Thursday, 22 February, 2018

Pfizer shares rise after Q4 profit, revenue beats; upbeat guidance

FSMNews SEC FORM 4 - SEC.gov
Nellie Chapman | 30 January, 2018, 21:05

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 1st. The institutional investor held 1.64M shares of the health care company at the end of 2017Q3, valued at $58.56M, down from 1.75M at the end of the previous reported quarter. PFE has a net profit margin of 18.90% and is more profitable than the average company in the Drug Manufacturers - Major industry. Analysts had anticipated revenues of $53.88 billion and EPS of $2.78. They expect $0.56 EPS, up 19.15% or $0.09 from last year's $0.47 per share. The company's revenue for the quarter was up.9% on a year-over-year basis.

Shares of Pfizer fell 1.9 percent to $38.30 in pre-market trading. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. (NYSE:PFE). Altavista Wealth Management holds 0.77% of its portfolio in Pfizer Inc.

PFE is available at a PE (price-to-earnings) ratio of 23.9x today, which tells us the stock is undervalued based on its latest annual earnings update compared to the pharmaceuticals average of 24.23x, and overvalued compared to the U.S. market average ratio of 20.07x. Acropolis Investment Management LLC increased its stake in shares of Pfizer by 6.7% in the 2nd quarter. This represents a $1.36 annualized dividend and a yield of 3.49%. Pfizer's dividend payout ratio is 79.01%.

Several other analysts have also recently commented on PFE. BMO Capital Markets set a $39.00 price target on Pfizer and gave the stock a "buy" rating in a research note on Wednesday, January 24th. Deutsche Bank maintained the shares of PFE in report on Wednesday, October 28 with "Buy" rating. BMO Capital Markets set a $37.00 target price on shares of Pfizer and gave the company a "buy" rating in a report on Tuesday, October 10th. ValuEngine upgraded shares of Pfizer from a "hold" rating to a "buy" rating in a report on Friday, October 6th.

Among 9 analysts covering Flexion Therapeutics (NASDAQ:FLXN), 9 have Buy rating, 0 Sell and 0 Hold.

Heading into the earnings release, covering sell-side analysts have a consensus target price of $38.57 on Pfizer Inc. shares.

In other news, insider Alexander R. Mackenzie sold 14,700 shares of the business's stock in a transaction on Wednesday, November 1st. Value investors will surely go for the low or decreasing P/FCF totals and reasonably low stock share prices. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company's stock valued at $160,000 after buying an additional 265 shares during the period. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

On 12/15/2017 Rady A Johnson, EVP, sold 8,000 with an average share price of $37.07 per share and the total transaction amounting to $296,560.00. Following the sale, the executive vice president now owns 46,963 shares of the company's stock, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. The stock decreased 0.95% or $1.02 during the last trading session, reaching $105.82. (NYSE:PFE). Broderick Brian C invested in 19,383 shares or 0.25% of the stock. It is flat, as 11 investors sold UNF shares while 56 reduced holdings. only 17 funds opened positions while 54 raised stakes. Shine Investment Advisory Services Inc. bought a new stake in shares of Pfizer during the second quarter worth $102,000. The fund owned 113,900 shares of the biopharmaceutical company's stock after selling 6,000 shares during the quarter.

Pfizer Inc. (PFE) held 5.69 billion outstanding shares now. Vanguard Group Inc. grew its stake in Pfizer by 2.3% in the second quarter. Swedbank now owns 3,754,276 shares of the biopharmaceutical company's stock valued at $126,106,000 after buying an additional 77,690 shares during the period. Shares buyback plans are typically a sign that the company's management believes its stock is undervalued. M&R Capital Management Inc who had been investing in Lowes Cos Inc Com for a number of months, seems to be bullish on the $87.81 billion market cap company.

Pfizer declared that its Board of Directors has initiated a share repurchase plan on Monday, December 18th that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the biopharmaceutical company to buy shares of its stock through open market purchases. If you are reading this story on another publication, it was illegally stolen and republished in violation of United States & global trademark and copyright law.